Monocyte Targeting Technology

Monocytes are key drivers of the inflammatory process and maintain the chronic stage in various inflammatory diseases.
Monocytes are a type of immune cell that forms in the bone marrow and travel through the blood to inflamed tissues.

VBL has developed its Monocyte Targeting Technology (MTT), as an investigational new and specific way to limit chronic inflammation. Our program is based on the discovery of a novel target protein that is selectively expressed on the surface of monocytes and controls their ability to migrate (or 'walk' to) inflamed tissues. This protein is called MOSPD2 (the "mono-walk" receptor).

Our lead MTT candidate, VB-601, is an investigational proprietary monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor and is engineered to specifically block the ability of monocytes to reach inflamed tissues. VB-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents, most of which target pro-inflammatory molecules and work through T and B lymphocytes but are not targeted to the monocyte cells.

VB-601 aims to offer a novel and differentiated mechanism to treat inflammation:

Inflamed tissue and cells. There is no ability for monocytes to be targeted.

The Problem

There is no treatment specifically targeting monocytes, key immune cells controlling the inflammatory response. Several drugs target and inhibit T cell or B cell mediated immune response, but the inflammation persists.

VBL-601 binds with monocytes. Inflammation is restrained.

Our Solution

VB-601 is an antibody that specifically targets the MOSPD2 “mono-walk” receptor. By binding MOSPD2, VB-601 locks monocytes in a `sticky` state, blocking them from reaching the inflammatory tissue.

Differentiated Approach

Instead of trying to overcome the redundancy of chemo attractants & receptors, VB-601 puts the brakes on the monocytes ability to move, arresting them in the perivascular space.

VBL intends to initiate a first-in-human study of VB-601 in the first quarter of 2023.

Based on our pre-clinical and human ex-vivo data, we believe VB-601 has potential utility in a wide range of immune-inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, non-alcoholic steatohepatitis (NASH), inflammatory bowel disease and other immune-inflammatory diseases.

Frequently Asked Questions